Clinical Trials Browser

INDUSTRY × Interventional × bemarituzumab × Clear all

Stomach Neoplasms

NCT05325866 2026-02-04

FORTITUDE-301

BreastGastrointestinalGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05111626 2025-12-15

FORTITUDE-102

Phase 3 Active not recruiting

515 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05322577 2025-12-05

FORTITUDE-103

Phase 1/2 Active not recruiting

72 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05267470 2025-03-25

FORTITUDE-201

Phase 1 Terminated

74 enrolled 22 charts

Thoracic

Squamous-Cell Non-Small-Cell Lung Cancer

NCT02318329 2024-06-04

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

Phase 1 Completed

79 enrolled 21 charts

GastrointestinalGenitourinary

Urinary Bladder Neoplasms, Esophageal Neoplasms, Stomach Neoplasms

NCT03343301 2024-02-28

FIGHT

Phase 1 Completed

12 enrolled 17 charts

Gastrointestinal

Gastrointestinal Neoplasms, Stomach Neoplasms

NCT03694522 2024-02-28

FIGHT

Phase 2 Completed

155 enrolled 19 charts

Gastrointestinal

Stomach Neoplasms

NCT05913115 2023-06-22

A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer

Phase 1 Completed

6 enrolled

Gastrointestinal

Gastric or Gastroesophageal Cancer

Clinical Trials

FORTITUDE-101

FORTITUDE-301

FORTITUDE-102

FORTITUDE-103

FORTITUDE-201

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

FIGHT

FIGHT

A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer